WO2001096599A3 - Methods for quantitative determination of b-fibronectin in biological fluids and tissues - Google Patents

Methods for quantitative determination of b-fibronectin in biological fluids and tissues Download PDF

Info

Publication number
WO2001096599A3
WO2001096599A3 PCT/EP2001/006533 EP0106533W WO0196599A3 WO 2001096599 A3 WO2001096599 A3 WO 2001096599A3 EP 0106533 W EP0106533 W EP 0106533W WO 0196599 A3 WO0196599 A3 WO 0196599A3
Authority
WO
WIPO (PCT)
Prior art keywords
quantitative determination
biological fluids
fibronectin
tissues
methods
Prior art date
Application number
PCT/EP2001/006533
Other languages
French (fr)
Other versions
WO2001096599A2 (en
Inventor
Patrizia Castellani
Luciano Zardi
Andries Zijlstra
Original Assignee
Philogen Srl
Patrizia Castellani
Luciano Zardi
Andries Zijlstra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philogen Srl, Patrizia Castellani, Luciano Zardi, Andries Zijlstra filed Critical Philogen Srl
Priority to AU2001281824A priority Critical patent/AU2001281824A1/en
Publication of WO2001096599A2 publication Critical patent/WO2001096599A2/en
Publication of WO2001096599A3 publication Critical patent/WO2001096599A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Quantitative determination of fibronectin isoform B (B-FN) and other insoluble marker proteins, including quantitative determination of B-FN in plasma and other biological fluids, employing gelatin that binds B-FN, also quantitative determination of insoluble marker proteins such as B-FN in tissue. Provision of quantitative information on angiogenesis through detection of B-FN as an indicator of malignancy in neoplasia.
PCT/EP2001/006533 2000-06-15 2001-06-08 Methods for quantitative determination of b-fibronectin in biological fluids and tissues WO2001096599A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001281824A AU2001281824A1 (en) 2000-06-15 2001-06-08 Methods for quantitative determination of b-fibronectin in biological fluids and tissues

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21167700P 2000-06-15 2000-06-15
US60/211,677 2000-06-15

Publications (2)

Publication Number Publication Date
WO2001096599A2 WO2001096599A2 (en) 2001-12-20
WO2001096599A3 true WO2001096599A3 (en) 2003-04-17

Family

ID=22787905

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/006533 WO2001096599A2 (en) 2000-06-15 2001-06-08 Methods for quantitative determination of b-fibronectin in biological fluids and tissues

Country Status (2)

Country Link
AU (1) AU2001281824A1 (en)
WO (1) WO2001096599A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2400622A1 (en) 2000-02-24 2001-08-30 Eidgenossische Technische Hochschule Zurich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
EP1514561A1 (en) * 2003-09-10 2005-03-16 Philogen S.p.A. Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B
GB0414886D0 (en) * 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
CN110110768B (en) * 2019-04-24 2021-02-26 西安电子科技大学 Rolling bearing fault diagnosis method based on parallel feature learning and multiple classifiers

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0355882A1 (en) * 1988-08-11 1990-02-28 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Method for the preparation of fibronectine from blood plasma, with the help of affinity chromatography and the column material to be used with it
WO1990008833A1 (en) * 1989-02-02 1990-08-09 Massachusetts Institute Of Technology Expression of recombinant fibronectin in genetically engineered cells
WO1997045544A1 (en) * 1996-05-24 1997-12-04 Philogen S.R.L. Antibodies to the ed-b domain of fibronectin, their construction and uses
WO1999015647A1 (en) * 1997-09-23 1999-04-01 Garvan Institute Of Medical Research A potential effector for the grb7 family of signalling proteins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0355882A1 (en) * 1988-08-11 1990-02-28 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Method for the preparation of fibronectine from blood plasma, with the help of affinity chromatography and the column material to be used with it
WO1990008833A1 (en) * 1989-02-02 1990-08-09 Massachusetts Institute Of Technology Expression of recombinant fibronectin in genetically engineered cells
WO1997045544A1 (en) * 1996-05-24 1997-12-04 Philogen S.R.L. Antibodies to the ed-b domain of fibronectin, their construction and uses
WO1999015647A1 (en) * 1997-09-23 1999-04-01 Garvan Institute Of Medical Research A potential effector for the grb7 family of signalling proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CASTELLANI P. ET AL.: "The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis.", INT. J. CANCER, vol. 59, 1 December 1994 (1994-12-01), pages 612 - 618, XP000960445 *
CLAUDEPIERRE P ET AL.: "Increased Ed-B fibronectin plasma levels in spondyloarthropathies: comparison with rheumatoid arthritis patients and a healthy population.", RHEUMATOLOGY, vol. 38, 1999, pages 1099 - 1103, XP002207493 *
D'OVIDIO MC ET AL.: "Intratumoral microvessel density and expression of ED-A/ED-B sequences of fibronectin in breast carcinoma.", EUR. J. CANCER, vol. 34, no. 7, 1998, pages 1081 - 1085, XP004284989 *

Also Published As

Publication number Publication date
WO2001096599A2 (en) 2001-12-20
AU2001281824A1 (en) 2001-12-24

Similar Documents

Publication Publication Date Title
Rosen et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer
EP1731619A3 (en) Tumour markers
HK1036834A1 (en) Differential diagnosis of neurodegeneration
WO2002057787A3 (en) Detection of survivin in the biological fluids of cancer patients
DK1084145T3 (en) Antibodies against the ED-B domain of fibronectin, conjugates containing them and their use in the diagnosis and treatment of tumors and diseases associated with angiogenesis
MXPA04000062A (en) Homocysteinylated transthyretin.
ES2143434A1 (en) Diaper with indicators sensitive to the status of the impregnated urine and visible from outside
AU1671300A (en) Cancer detection method and reagents
DE60129151D1 (en) METHOD FOR DETECTING EGG CANCER BY MEANS OF HUMAN CALLIQUE (HK6)
WO2002037112A3 (en) Detection of ovarian cancer
WO2003033731A3 (en) Methods for detecting ovarian cancer
WO2001025791A3 (en) Prostate cancer marker proteins
DE50207866D1 (en) USE OF SOLUBLE CYTOKERATIN-1-FRAGMENTS IN DIAGNOSTIC
WO2007020522A3 (en) Protein markers for diagnosing of colorectal cancer and use of said markers as drug targets for the treatment of said cancer type
WO2001096599A3 (en) Methods for quantitative determination of b-fibronectin in biological fluids and tissues
DK1173766T3 (en) Isoform of tenascin-C as a marker for neoplasia
WO2001083816A3 (en) Method for detecting tumors
WO2002023200A3 (en) Human breast cancer biomarkers
WO2003099107A3 (en) Methods and kits for the detection of renal cell carcinoma in a biological fluid of a patient
WO2002004952A3 (en) Diagnostic and therapeutic methods based on the l1 adhesion molecule for ovarian and endometrial tumors
WO2003023056A3 (en) Specific markers for multiple sclerosis
WO2001063293A8 (en) Diagnosis and treatment of schizophrenia
AU2606800A (en) Methods of determining an increased risk of a woman carrying a downs syndrome
WO2005039487A3 (en) Method for early detection of ovarian cancer
WO2003058198A3 (en) Human breast cancer biomarkers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP